Biogen Idec (BIIB) Updates on Four Growth Strategies for FY12

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 8/22/2026

1. WMT
2. ROST
3. AAP
4. NVDA
5. SPY
6. AVGO
7. SPCX
8. BJ
9. BABA
10. DE

January 9, 2012 9:08 AM EST
Biogen Idec (Nasdaq: BIIB) will present today its plans for driving the continued strong commercial performance of its existing multiple sclerosis (MS) treatments, preparing for the potential launches of multiple new high-impact therapies, advancing its late-stage pipeline, and leveraging its research and development (R&D) capabilities to grow its early-stage pipeline.

Biogen Idec is focused on executing on four key strategic priorities in 2012.
  • Grow its leadership position in MS by:
    • Advancing its AVONEX ® (interferon beta-1a) franchise through improvements such as a PEGylated form of interferon beta-1a that could potentially offer patients once-monthly or biweekly dosing.
    • Unlocking the value of TYSABRI® (natalizumab) by helping patients better understand their individual risk-benefit profile through risk stratification.
    • Expanding FAMPYRA®’s (prolonged-release fampridine tablets) footprint in Europe through additional launches and regulatory filings.
    Prepare for potential launch of multiple high-impact therapies by:
    • Filing for approval in the first half of this year for BG-12 in MS and building patient support services and specialty distribution.
    • Building the commercial team and patient services programs in hemophilia for its long-acting factor VIII and factor IX programs, which will both have data readouts this year.
    Advance late-stage pipeline by:
    • Delivering the data readout from the first Phase 3 trial of dexpramipexole in ALS by year-end.
    • Continuing to advance the daclizumab Phase 3 program in MS.
  • Drive innovation and grow early-stage pipeline by:
    • Building world-class scientific teams in its core therapeutic areas.
    • Advancing the company’s internal early-stage pipeline programs.
    • Advancing existing strategic collaborations, including those with Portola Pharmaceuticals, Inc. and Isis Pharmaceuticals, Inc., and entering into additional collaborations in neurology, immunology and hemophilia.
    • Continuing to focus its research and early discovery efforts.
    • Increasing its emphasis on translational research, including biomarker and imaging technologies, to drive better decision-making.
In addition, through its joint venture with Samsung, Biogen Idec expects to leverage its expertise and capabilities in protein engineering, cell line development and recombinant biologics manufacturing to position the company to participate in the emerging market for biosimilars.

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In





Related Categories

Corporate News, FDA, Guidance